Philippine Health Research Registry
Display Options
Results List
Results 1 - 5 of 5 research(es) registered in February 2018

Show: All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

#
Study
         
Project Status:
Pending
Project Description:
This study is a single-blind, multi-center, randomized, active-controlled, parallel group, phase II study designed to evaluate the safety and immunogenicity of LBVE compared with Prevnar13 given with 3 doses vaccinations in healthy infants.
Project Status:
Ongoing
Project Description:
This is a multicenter, multinational, double-blind, 1:1 randomized, parallel-group, equivalence Phase 3 study to compare the efficacy and safety of MB02 plus chemotherapy (carboplatin and paclitaxel) versus Avastin® plus chemotherapy (carboplatin and paclitaxel) in subjects with Stage IIIB/IV non-squamous NSCLC. MB02/Avastin® plus chemot... [read more]
Project Status:
Ongoing
Project Description:
This will be a Phase IIb, randomized, double-blind, placebo-controlled multicenter study. Study patients will be enrolled into one of the two treatment groups and allocated in a 1:1 randomization ratio to receive IFN-K or placebo as outlined below:  Group 1: IFN-K emulsified in ISA 51 VG  Group 2: placebo emulsified in ISA 51 VG A total of 17... [read more]
Project Status:
Ongoing
Project Description:
This is a randomised, double-blind, parallel group, placebo-controlled study designed to evaluate the efficacy and safety of a fixed 30 mg dose of benralizumab administered subcutaneously (SC) for patients with a history of asthma exacerbations and uncontrolled asthma receiving medium to high-dose inhaled corticosteroid plus long-acting β2-agonist... [read more]
Project Status:
Ongoing
Project Description:
This study is a 2-treatment period, randomized, multicenter parallel-group safety study (Figure 3-1). Treatment Period 1 is a 52-week, double-blind treatment period in which QAW039 or placebo is added to GINA steps 3, 4 and 5 SoC asthma therapy. Treatment Period 2 is an optional 104-week, single-blind treatment period in which patients will receive... [read more]